If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. Alcohol interacts with warfarin through

A             CYP450 1A2

B             Alcohol dehydrogenase

C             Interaction has not been clearly defined

D            p-Glycoprotein

2. The greatest risk of fetal abnormalities related to warfarin use occurs during

A             The first trimester

B             The second trimester

C             The third trimester

D            stable throughout pregnancy

3. The optimal duration of follow-up for patients receiving warfarin is:

A             Weekly

B             Monthly

C             Every 12 weeks

D            Not clearly defined in the literature

4. When using enoxaparin during pregnancy for the prevention of VTE in patients who have been receiving long term warfarin therapy:

A             Use near therapeutic treatment level doses adjusted for body weight

B             Use standard prophylactic doses

5. Antiphospholipid antibody syndrome:

A             Decreases the levels of Factor II and X

B             is associated with an Increase in the risk of hemorrhagic complications

C             is a viral disease

D            May interfere with the INR measurement of patients receiving warfarin

6. Alcohol

A             Should be avoided at any level in all patients receiving warfarin

B             Can be managed similar to other drug interactions

C             Multiple studies on the interaction between binge drinking and warfarin have been published

D            Alcoholism is a FDA labeled contraindication to the use of warfarin

7. The risk of thrombosis in pregnant women with mechanical heart valves is

A             Lowest in patients being treated with warfarin

B             Lowest in patients being treated with a LMWH

8. No major group of international experts have supported the notion testing the INR in a patient receiving warfarin as little as once every 3 months

A             True

B             False

9. A clinically appropriate way to monitor a patient receiving warfarin with antiphospholipid antibody syndrome is:

A             Factor II activity level

B             Factor X activity level

C             Activated Clotting Time (ACT)

D            Both A and B

10. Binge drinking of alcohol in an anti-coagulated patient increase the risk of

A             Falls

B             Gastrointestinal bleeding

C             Non-compliance

D            All of the above

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. Which of the following is NOT a catalyst for the coagulation cascade?
a. Tissue Factor
b. Collagen
c. Negatively charged phospholipid surfaces
d. Positively charged phospholipid surfaces

2. The following is true regarding VKOR, except:
a. It is an enzyme
b. It is the target of warfarin’s mechanism of action
c. It binds to negatively charged phospholipids in the presence of calcium
d. It recycles vitamin K epoxide to active vitamin KH2

3. Which if the following is not a contraindication for warfarin therapy?
a. Pregnancy
b. Major surgery or trauma
c. Active bleeding
d. Spinal puncture
e. Asymptomatic PE

4. DE is a 60 year old male being referred to your anticoagulation clinic with a diagnosis of new onset atrial fibrillation. DE’s past medical history is significant for hypertension, hypercholesterolemia, rheumatoid arthritis, and type 2 diabetes mellitus. Based on the CHEST guidelines, what duration of warfarin therapy do you recommend for DE? Why?
a. 3 months to indefinite, CHADS score of 2
b. Indefinite, CHADS score of 4
c. Indefinite, CHADS score of 2
d. Aspirin therapy preferred over warfarin in this patient
e. None of the above

5. ML is a 65 year old female being referred to your anticoagulation clinic with a s/w new mechanical heart valve in the mitral position. What duration of warfarin therapy and INR goal do you recommend for ML?
a. 2-3; Indefinite therapy
b. 2-3; 3-6 months
c. 2.5-3.5; Indefinite therapy
d. 2.5-3.5; 3-6 months
e. 1.5-2; Indefinite therapy
f. Warfarin is not recommended

6. AL is a 48 year old female who is on warfarin therapy with an indication of mechanical heart valve in the aortic position. Her INR goal is 2-3. Today AL’s INR returned at 1.6. She reports no pertinent findings. The patient take 7.5 mg on Monday and 5 mg on all other days.
a. What are your next steps for this patient?
b. No Change. Continue current warfarin dosing.
c. Instruct the patient to take warfarin 5 mg daily
d. Instruct the patient to take warfarin 7.5 mg on M/F and 5 mg on all other days
e. Instruct the patient to take warfarin 10 mg daily
f. Contact the clinician. The patient’s INR goal is incorrect

7. When considering warfarin dosage adjustments, which of the following patient specific factors is important to consider?
a. Dietary vitamin K intake
b. Upcoming dental procedure
c. Newly started amiodarone
d. History of patient non-adherence
e. All of the above

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1.  The Prothrombin time is prolonged in patients:

1. Receiving warfarin
2. With significant liver disease
3. on a typical dose of enoxaparin
4. both A and B

2.  A patient receiving warfarin may also be monitored by checking the activity level of:

1. Anti-factor Xa
2. Factor II
3. D-dimer
4. fibrinogen

3.  Useful tests to screen for a coagulation disorder in a bleeding patient include

1. aPTT and PT
2. TT and PT
3. D-dimer and aPTT
4. ACT and aPTT

4.  The activity of heparin can be monitored with

1. aPTT
2. Anti factor-Xa
3. ACT
4. all of the above

5.  Anti-factor Xa test is

1. test of clotting time
2. functional test of enzymatic activity

6.  Very high doses of unfractionated heparin are best measured with

1. TT
2. ACT
3. aPTT
4. PT

7.  This test measures the last step in the coagulation cascade, the conversion from fibrinogen to thrombin:

1. TT
2. ACT
3. aPTT
4. PT

8.  If the patient’s PT is 39, the control PT is 13, and the sensitivity of the reagent is 1, what is the INR

1. more info is needed
2. 2.0
3. 3.0
4.  1.0

9.  Antiphospholipid Antibody Syndrome:

1. Is a clinical condition predisposing patients to hemorrhagic complications
2. May interfere with PT/INR testing leading to a false prolongation
3. Predisposes the patient to a pro-thrombotic state and may falsely shorten the PT test
4. Can easily be corrected for by the lab through analytical methods.

10.  Argatroban use is not expected to significantly affect the monitoring of warfarin.

1. True
2. False

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1.  The newer oral anticoagulants work by:

1. Indirectly inhibiting factor VIII
2. Directly inhibiting factor IIa or Xa
3. Causing the breakdown of fibrin
4. Decreasing the production of factor II

2. p-Glycoprotein inhibition leads to

1. Increased substrate serum levels
2. Decreased substrate serum levels
3. Increased metabolism of substrate
4. No effect

3. Which agent was shown to be superior to warfarin in both safety and efficacy in atrial fibrillation

1. Dabigatran
2. Rivaroxaban
3. Apixaban
4. None of the above

4. There is no evidence to suggest that pharmacists can impact the care of patients receiving the new oral agents.

1. True
2. False

5. For the treatment of an acute venous thromboembolism, initial parenteral anticoagulants are not needed for therapy with:

1. Dabigatran or Rivaroxaban
2. Rivaroxaban or Apixaban
3. Apixaban or Edoxaban
4. A parenteral anticoagulant is always needed for at least the first week.

6. This drug should not be placed in a pill box

1. Dabigatran
2. Rivaroxaban
3. Apixaban
4. Edoxaban

7. What type of patient would be considered a good candidate to for DOAC therapy?

1. Documented warfarin allergy
2. History of poor INR control on warfarin despite good compliance
3. Considerable barriers to routine monitoring, such as physical or transportation issues
4. Document and confirmed warfarin failure such as an ischemic stroke while consistently therapeutic on warfarin
5. All of the above

8. To switch a patient from subcutaneously LMWH to a DOAC, you would recommend to discontinue the LMWH and then…

1. begin the new agent 3 days later if the patient has normal renal function
2. begin the new agent when the patient’s PTT and INR are sub-therapeutic
3. bridge with LMWH and the DOAC for 24 hours
4. begin the new agent when the next dose of LMWH would be due

9. Which of the following DOACs’ bioavailability substantially increases when it is taken with food (largest meal of the day)?

1. Edoxaban
2. Rivaroxaban
3. Dabigatran
4. Apixaban

10. Prior to initiating a DOAC, the patient should be evaluated for which the following?

1. Renal Clearance
2.  Appropriate and approved indication for the specific DOAC agent
3. Review of patient medication profile to check for potentially significant drug-drug interactions
4. Adequate insurance coverage or prescription assistance before starting the DOAC agent
5. All of the above

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. You get a phone call from a nurse, concerned that her patient with a new blood clot and being treated with heparin is going for dialysis today. She is unsure of how this will affect the patient’s heparin therapy. You respond:
a. You advise the nurse the patient will require an additional bolus dose of heparin after dialysis.
b. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to LMWH.
c. You advise the nurse that dialysis will not affect heparin levels and it is safe to continue therapy without any intervention.
d. You advise the nurse to increase the heparin rate during dialysis.
e. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to argatroban.

2. The following is true regarding low molecular weight heparins, except:
a. LMWH share a common pentasaccharide sequence that enables binding to antithrombin and thrombin
b. Protamine will not completely reverse LMWH effects
c. Dose adjustments are necessary for CrCl <30 ml/min d. Due to longer half life, once or twice daily dosing is possible e. All of the above are true 3. Low molecular weight heparins are approved for all of the following indications, except: a. Prevention of venous thromboembolism b. Treatment of venous thromboembolism c. Anticoagulation in patients with a history of HIT d. Acute coronary syndromes e. All of the above 4. TY, a 70 year old male is admitted to your hospital with an community acquired pneumonia. He is started on IV antibiotics, albuterol nebulizers, and IV fluids. He has no allergies. His INR on admission is 1.1. His BUN/Scr = 30/2.5 He is 5’5” and 75 kg. On interdisciplinary rounds, the attending physician asks for any pharmacological recommendations for this patient. You suggest that VTE prophylaxis should be considered if the patient does not have any contraindications to it. The patient does not have any contraindications, and the physician asks for your recommendation for choice of therapy. The most appropriate recommendation is: a. Enoxaparin 40mg SC daily b. IV Heparin per thromboembolic protocol c. Fondaparinux 2.5mg SC daily d. Enoxaparin 30mg SC daily e. Tinzaparin 13,125 anti Xa international units SC daily 5. The following are true about BOTH LMWH and fondaparinux, except: a. Dose adjustment or avoidance of use is necessary in patients with impaired renal function b. Anti Xa testing is recommended for most patients, and should be drawn on days 2 and 4 of therapy c. Active bleeding is a contraindication for use d. Both are associated with lower risk for development of HIT vs. heparin e. Both are indicated for the treatment and prophylaxis of VTE

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. Comparing 4-factor PCC to 3- Factor PCC, what factor is not included in the “3”?

1. II
2. VII
3. IX
4. X

2. We consider anticoagulation to have resolved fully after _____half-lives have lapsed:

1. Four
2. Five
3. Six
4. Two

3. What differentiates major bleeding vs. non-major?

1. Hemodynamically unstable
2. Requires transfusion ≥ 2 units
3. Decrease of hemoglobin ≥ 2 g/dL
4. All of the above

4. When reversing the effects of warfarin, vitamin K is not needed when administering FFP or KCentra

1. True
2. False

5. Which of the following routes of administration is not appropriate for a bleeding patient?

1. IV
2. SQ
3. PO
4. IM

6. The correct full dose of idarucizumab is:

1. 5 gms
2. 5 gms
3. 5 gm
4. 50 units/kg

7. In general, the maximum dose of vitamin K for warfarin reversal is:

1. 5mg
2. 10mg
3. 15mg
4. 20mg

8. What anticoagulation agent may utilize hemodialysis as a form of reversal?

1. Apixaban
2. Rivaroxaban
3. Dabigatran
4. Warfarin

9. What agent is specifically used to directly reverse the effect Rivaroxaban and Apixaban

1. Idarucizumab
2. 4-factor PCC
3. Andexanet afla
4. Phytonidione

10. True or False: Obtaining and administering reversal agents must not delay resuscitation and local hemostatic measures.

1. True
2. False

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour